Our patient was a 36-year-old female diagnosed with Grade II ER+/PR−/Her-2 − ductal carcinoma in situ (DCIS) in the left breast. She underwent left lumpectomy and received treatment with tamoxifen and radiotherapy. Three years later, she presented with multiple diffused skin nodules on the chest and upper left arm. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) exam showed widespread metastasis in the chest, upper left arm, left axillary lymph nodes, and left suprascapular muscle. FDG-PET/CT imaging of breast carcinoma en cuirasse is very rare. FDG-PET/CT is useful in detecting recurrent breast cancer.
INTRODUCTION
The major sites of breast cancer metastasis in decreasing prevalence are the lungs, bone, liver, adrenal, and brain. [1] Cutaneous metastasis from internal malignancies is rare with a reported incidence between 0.7% and 9% and it may be a sign of cancer recurrence. [2] Skin metastases from breast cancer have many forms: Telangiectatic carcinomas, erysipeloid carcinomas, "en cuirasse" carcinomas, alopecia neoplastica, and a zosteriform type. [3] Carcinoma en cuirasse is very rare and occurs in only 3% of cutaneous metastasis cases. [3] Carcinoma en cuirasse is caused by lymphatic spread. Carcinoma en cuirasse is described as small, multiple erythematous nodules which can enlarge and coalesce to form plaques. [3] 18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (FDG-PET/CT) can scan the whole body for metastases in one exam, whereas serial CTs are required to accomplish the same task.
CASE REPORT
The patient was a 36-year-old female who presented with pain under the left arm. The ultrasound revealed a 2.5 cm irregular mass in the upper outer quadrant of the left breast and a subsequent mammogram showed an asymmetric density in the same region. Left lumpectomy removed a 4.9 cm mass and pathology confirmed it as ER+/PR−/Her-2− intermediate-grade ductal carcinoma in situ (DCIS) with positive margins. Left breast re-excision was done and there was no evidence of residual disease. Sentinel lymph node biopsy was negative and FDG-PET/CT showed only postsurgical changes [ Figure 1 ]. She was 
DISCUSSION
FDG-PET imaging of breast carcinoma en cuirasse is very rare. This is the first case to show FDG-PET/CT images of suprascapular muscle metastasis from breast cancer. Skeletal muscle is an unusual site for breast cancer metastasis and it occurs by the hematogenous route. [4] The chest is the most common site of cutaneous metastasis. [1] Abdomen, back, and upper extremities are less common sites of skin metastasis. [5] In our patient, cutaneous metastasis occurred in the chest and left upper extremity. Our patient was first diagnosed with breast cancer at the age of 36 and breast cancer in this age group is very rare. [6] Young age (less than 40 years) is an independent predictor of tumor recurrence following breast-conserving surgery. [6] Our patient had lumpectomy in the left breast and the cancer recurred 3 years after the surgery. According to the biopsy report, she had ER+/PR−/Her-2− ductal carcinoma. Interestingly, younger patients with ER +ve tumors have a poorer disease-free survival than those with ER −ve tumors. [7] Ultrasound (US) and CT mostly focus on the size of the lymph nodes, while FDG-PET/CT looks at the biological activity of tumors. Intramuscular hot spots on PET/CT scans should be considered as a sign of metastasis, even in the absence of abnormalities on CT scans. [8] It is difficult to detect skeletal muscle metastasis with the generally used CT scans. [8] In the present case, the extent of breast cancer recurrence was clearly demonstrated by the PET/CT exam. FDG-PET/CT has 93% sensitivity and 100% specificity in detecting breast cancer recurrence. [4] Aukema et al., even suggested that PET/CT can replace conventional imaging in patients with breast cancer recurrence. [9] CONCLUSION PET scanning can reveal unexpected sites of metastasis. This case has demonstrated that FDG-PET/CT is useful in demonstrating the extent of breast cancer recurrence. Skin lesions in a patient with history of breast cancer should raise the suspicion of cancer recurrence.
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